




CCR8 Recombinant Monoclonal Antibody

Product Code	CSB-RA004847A1HU
Storage	Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Uniprot No.	P51685
Immunogen	Recombinant Human CCR8 protein
Species Reactivity	Human
Tested Applications	FC
Form	Liquid
Conjugate	Non-conjugated
Storage Buffer	Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Purification Method	Affinity-chromatography
Isotype	hIgG1
Clonality	Monoclonal
Product Type	Recombinant Antibody
Immunogen Species	Homo sapiens (Human)
Research Area	Immunology;Microbiology
Gene Names	CCR8
Clone No.	2C6

Image



Untransfected HEK293T cells surface (green line) and transfected Human CCR8 HEK293T stable cells surface (red line) were stained with anti-CCR8 antibody ($2\mu\text{g}/1*10^6$ cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.

Description

The DNA sequence corresponding to the CCR8 monoclonal antibody produced from the animals through recombinant human CCR8 immunization was cloned into the expression vector, which was further transfected into a cell line for in vitro expression. The product is the recombinant CCR8 monoclonal antibody. It specifically targets the CCR8 from human. It belongs to the human IgG1. The affinity-chromatography purification method was used to purify this CCR8 antibody. The flow cytometry analysis has been tested for this CCR8 antibody.



Joseph R. Campbell et al. found that selective ablation of regulatory T cells with an anti-DHFR antibody can potentiate anti-tumor immune responses as a monotherapy or in combination with other immunotherapies. Daniel O. Villarreal *et al.* showed that anti-DHFR monoclonal antibody therapy, in synergy with the *Listeria monocytogenes*-based immunotherapy, remarkably retarded the growth of the established tumor and prolonged survival.